Bogdan Mitran

List of Publications by Year
in descending order

48 papers	1,146 citations	331670 21 h-index	434195 31 g-index
48 all docs	48 docs citations	48 times ranked	1133 citing authors

#	Article	IF	Citations
1	Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancerâ€"Optimization of the Affinity towards PSMA by Linker Modification in Murine Model. Pharmaceutics, 2020, 12, 614.	4.5	19
2	Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer. Molecules, 2020, 25, 5993.	3.8	6
3	Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules. International Journal of Molecular Sciences, 2020, 21, 1972.	4.1	9
4	Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties. Current Medicinal Chemistry, 2020, 27, 7090-7111.	2.4	9
5	Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart. Pharmaceutics, 2019, 11, 380.	4.5	6
6	Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer. Pharmaceutics, 2019, 11, 358.	4.5	17
7	Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer. Cancers, 2019, 11, 1371.	3.7	26
8	Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111. Scientific Reports, 2019, 9, 655.	3.3	18
9	Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 140, 109-120.	4.3	21
10	Trastuzumab cotreatment improves survival of mice with PCâ€3 prostate cancer xenografts treated with the GRPR antagonist ¹⁷⁷Luâ€DOTAGAâ€PEG₂â€RM26. International Journal of Cancer, 2019, 145, 3347-3358.	5.1	30
11	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. Scientific Reports, 2019, 9, 6779.	3.3	8
12	Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting. Biomaterials, 2019, 203, 73-85.	11.4	19
13	Comparison of tumorâ€targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2. International Journal of Oncology, 2019, 54, 1209-1220.	3.3	19
14	Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers. International Journal of Molecular Sciences, 2019, 20, 1080.	4.1	21
15	Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26. Scientific Reports, 2019, 9, 17086.	3.3	14
16	Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. Scientific Reports, 2019, 9, 14907.	3.3	14
17	Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. Scientific Reports, 2019, 9, 17710.	3.3	14
18	Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 134, 37-48.	4.3	21

#	Article	IF	Citations
19	Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. Molecular Pharmaceutics, 2019, 16, 995-1008.	4.6	35
20	Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acidâ€“Mediated Pretargeting: In Vivo Proof of Principle. Journal of Nuclear Medicine, 2018, 59, 1092-1098.	5.0	48
21	Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules. Amino Acids, 2018, 50, 981-994.	2.7	16
22	Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label. Journal of Nuclear Medicine, 2018, 59, 93-99.	5.0	29
23	Cyclic versus Noncyclic Chelating Scaffold for ⁸⁹Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. Molecular Pharmaceutics, 2018, 15, 175-185.	4.6	31
24	Affibodyâ€‘mediated imaging of EGFR expression in prostate cancer using radiocobaltâ€‘labeled DOTAâ€‘ZEGFR:2377. Oncology Reports, 2018, 41, 534-542.	2.6	4
25	Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors. Cells, 2018, 7, 141.	4.1	21
26	Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model. Theranostics, 2018, 8, 4462-4476.	10.0	25
27	Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors. Journal of Controlled Release, 2018, 288, 84-95.	9.9	40
28	Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy. Scientific Reports, 2018, 8, 9643.	3.3	11
29	Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. Contrast Media and Molecular Imaging, 2018, 2018, 1-11.	0.8	30
30	Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with ¹¹¹In and ⁶⁸Ga. Molecular Pharmaceutics, 2018, 15, 2674-2683.	4.6	15
31	In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. Scientific Reports, 2017, 7, 43118.	3.3	20
32	Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting: Development of an optimized conjugation protocol and 177 Lu labeling. Nuclear Medicine and Biology, 2017, 54, 1-9.	0.6	24
33	The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule. Scientific Reports, 2017, 7, 5961.	3.3	29
34	Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m. Scientific Reports, 2017, 7, 14780.	3.3	17
35	High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26. Contrast Media and Molecular Imaging, 2017, 2017, 1-10.	0.8	27
36	Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression. International Journal of Oncology, 2017, 51, 1765-1774.	3.3	10

#	Article	IF	Citations
37	PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules. International Journal of Oncology, 2016, 48, 1325-1332.	3.3	50
38	Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX. Molecular Pharmaceutics, 2016, 13, 3676-3687.	4.6	30
39	Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator. International Journal of Oncology, 2016, 49, 2285-2293.	3.3	27
40	Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6. Bioconjugate Chemistry, 2016, 27, 2678-2688.	3.6	13
41	Synthesis of ¹¹Câ€labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [¹¹C]CO. ChemistryOpen, 2016, 5, 566-573.	1.9	16
42	Feasibility of Affibody-Based Bioorthogonal Chemistryâ€“Mediated Radionuclide Pretargeting. Journal of Nuclear Medicine, 2016, 57, 431-436.	5.0	46
43	Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. International Journal of Oncology, 2016, 48, 2124-2134.	3.3	29
44	Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules. Molecular Pharmaceutics, 2016, 13, 1668-1678.	4.6	33
45	Affibody-mediated PET imaging of HER3 expression in malignant tumours. Scientific Reports, 2015, 5, 15226.	3.3	56
46	Evaluation of 99mTc-ZIGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. Amino Acids, 2015, 47, 303-315.	2.7	22
47	The effect of macrocyclic chelators on the targeting properties of the 68 Ga-labeled gastrin releasing peptide receptor antagonist PEG 2 -RM26. Nuclear Medicine and Biology, 2015, 42, 446-454.	0.6	46
48	The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a 68Ga-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin. Molecules, 2014, 19, 10455-10472.	3.8	55